Trial of Tocilizumab in Giant‐Cell Arteritis

By J. Stone, K. Tuckwell, S. Dimonaco, M. Klearman, M. Aringer, D. Blockmans, E. Brouwer, M. Cid, B. Dasgupta, J. Rech and 6 more. New England Journal of Medicine, 2017

1,122 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/1da930f85fcf3137bf5645b4637a4914faa1179f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. B. Hellmich
2. R. Watts
3. M. Cid
4. A. Águeda
5. G. Hatemi
6. S. Monti
7. R. Luqmani
8. A. Mahr

Citations in the corpus

• Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. (2020, methodology): “Patients were randomized after a median (interquartile range) time from symptom onset of 8 (6-11) days.”
• 2018 Update of the EULAR recommendations for the management of large vessel vasculitis (2019, positive): “2 LVV-specific patient-reported outcome instruments for use in clinical practice are not available, 38 136–138 and should be the subject of future research.”